Amneal Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AMRX | 3933.HK | ALKS | AMLX | THEMISMED.BO | INDSWFTLAB.BO | |
|---|---|---|---|---|---|---|
| Market cap | 6.95B | 15.37B | 7.71B | 3.69B | 9.36B | 31.71B |
| P/E (TTM) | 49.9 | 28.9 | — | — | 23.5 | 40.4 |
| Forward P/E | 16.4 | 11.3 | 25.4 | -27.0 | — | — |
| Price/book | 12.6 | 0.8 | 4.2 | 13.7 | 2.4 | 2.1 |
| Dividend yield | — | 6.47% | — | — | 0.50% | — |
| 1-year change | +72.88% | −41.08% | +47.06% | +120.54% | −16.36% | +239.52% |
| Today | −1.29% | +6.41% | +0.44% | +0.68% | +1.22% | −3.43% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All AMRX news ›What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
Posted by Danessa Lincoln on Nov 4th, 2026 Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an…
Amneal Reports Third Quarter 2026 Financial Results
- Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 - - Updating 2026 Full Year Guidance - BRIDGEWATER, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal” or the "Company”) today…
Amneal Pharmaceuticals Q3 2026 Earnings Preview
Amneal Pharmaceuticals (AMRX) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, before market open. The consensus EPS estimate is $0.24 (+4 - Amneal Pharmaceuticals (AMRX) is scheduled to announce Q3 earnings results…
NJEDA approves manufacturing award to boost Amneal Pharmaceuticals investment in state
Chirag Patel, co-founder and co-CEO of Amneal Pharmaceuticals. - Amneal The New Jersey Economic Development Authority board recently approved about $60 million in tax credits under the Next New Jersey Manufacturing Program to support a…
Leerink Partners Remains a Buy on Amneal Pharmaceuticals (AMRX)
In a report released today, Daniel Clark from Leerink Partners reiterated a Buy rating on Amneal Pharmaceuticals, with a price target of $23.00. According to TipRanks, Clark is a 3-star analyst with an average return of 9.0% and a 56.00%…
30,437 Shares of Amneal Pharmaceuticals, Inc. $AMRX Bought by Gibbs Wealth Management
Gibbs Wealth Management bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.…
Head to Head Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) & NRx Pharmaceuticals (NASDAQ:NRXP)
Posted by Tristan Rich on Oct 18th, 2026 NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) and Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com2
- defenseworld.net1
- manilatimes.net1
- roi-nj.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.